The information highlighted (if any) are the most recent updates for this brand.
Full Prescribing Info
Indications/Uses
Lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) whose disease has progressed after: alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or crizotinib and at least one other ALK TKI.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
